USE OF ERYTHROPOIETIN FOR THE TREATMENT OF FRIEDREICH´S ATAXIA: In addition to its neuro- and cardioprotective properties recombinant human erythropoietin (rhuEPO) significantly increases frataxin expression in primary lymphocytes from FApatients, and other cell types like neurons and primary human cardiac cells in vitro. (Sturm et.al 2005, Eur. J.Clin. Invest. 35(11):711-7) rhuEPO was successfully tested as a treatment for Friedreich`s ataxia in Phase IIa/IIb and dosefinding studies.
Further information: PDF
Wissenstransferzentrum Ost (WTZ Ost)
Phone: +43 1 401 60 25 202
Dr. Michael Hoschitz
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
email@example.com | TechnologieAllianz e.V.
New Lithium Salts of Pentafluorophenylamide Anions as Electrolytes in Lithium Ionic Batteries
18.04.2017 | TechnologieAllianz e.V.
Gratings on glass surfaces
28.03.2017 | TechnologieAllianz e.V.
19.09.2017 | Event News
12.09.2017 | Event News
06.09.2017 | Event News
20.09.2017 | Life Sciences
20.09.2017 | Power and Electrical Engineering
20.09.2017 | Physics and Astronomy